SCHEMBL10129490

SCHEMBL10129490

CC(C)(C)c1cn2ccccc2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.48
PTGS1 P23219 1/20 0.47
PTGS2 P35354 1/20 0.47
RAB9A P51151 12/20 0.46
NPC1 O15118 11/20 0.46
HDAC6 Q9UBN7 1/20 0.46
KDM4E B2RXH2 8/20 0.45
PKM P14618 3/20 0.45
EPHX2 P34913 1/20 0.45
POLB P06746 1/20 0.45
ALDH1A1 P00352 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
HPGD P15428 3/20 0.44
MAPK1 P28482 2/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
HSD17B10 Q99714 1/20 0.44
GFER P55789 3/20 0.44
ALOX12 P18054 1/20 0.44
NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30339144 0.85 RAB9A (0.46) SSTR4PTGS1PTGS2RAB9ANPC1
SCHEMBL9796679 0.85 SSTR4 (0.46) SSTR4PTGS1PTGS2RAB9ANPC1
SCHEMBL18517250 0.82 NPC1 (0.48) SSTR4PTGS1PTGS2RAB9ANPC1
SCHEMBL29320765 0.82 SSTR4 (0.47) SSTR4PTGS1PTGS2RAB9ANPC1
SCHEMBL161950 0.81 RAB9A (0.49) SSTR4PTGS1PTGS2RAB9ANPC1
SCHEMBL21239943 0.80 SSTR4 (0.45) SSTR4PTGS1PTGS2RAB9ANPC1
SCHEMBL22333551 0.80 SSTR4 (0.45) SSTR4PTGS1PTGS2RAB9ANPC1
SCHEMBL15679454 0.78 KDM4E (0.35) SSTR4PTGS1PTGS2RAB9ANPC1
SCHEMBL23562883 0.78 RAB9A (0.45) SSTR4PTGS1PTGS2RAB9ANPC1
SCHEMBL15979317 0.77 SSTR4 (0.44) SSTR4PTGS1PTGS2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043613-B2 Inhibitors of SARM1 DISARM THERAPEUTICS, INC. (US) 2024-07-23 US disclosed
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders PFIZER INC. (US) 2024-07-18 US disclosed
US-12016852-B2 Pyrrolidine glycosidase inhibitors ASCENEURON SA (CH) 2024-06-25 US disclosed
CN-117946101-A Aryl methyl sulfone compound and synthesis method thereof 中国人民解放军军事科学院防化研究院 2024-04-30 CN disclosed
US-11795165-B2 Tetrahydro-benzoazepine glycosidase inhibitors ASCENEURON SA (CH) 2023-10-24 US disclosed
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS UNIVERSITY OF OULU (FI) 2023-10-12 US disclosed
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS UNIVERSITY OF OULU (FI) 2023-10-12 US disclosed
US-20230295115-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-09-21 US disclosed
US-20230295115-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2023-09-21 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20090197883-A1 Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use MERCK SHARP & DOHME CORP. 2009-08-06 US disclosed
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2009-05-14 US disclosed
US-20080182839-A1 MODULATORS OF CELLULAR ADHESION SUNESIS PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed
US-20080182839-A1 MODULATORS OF CELLULAR ADHESION SUNESIS PHARMACEUTICALS, INC. (US) 2008-07-31 US disclosed
US-20080176896-A1 Modulators of cellular adhesion BAUSCH + LOMB IRELAND LIMITED (IE) 2008-07-24 US disclosed
US-20080176896-A1 Modulators of cellular adhesion BAUSCH + LOMB IRELAND LIMITED (IE) 2008-07-24 US disclosed
US-20080146539-A1 NEW CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-06-19 US disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed
US-7371743-B2 Carboxylic acid amides, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-13 US disclosed
US-7314938-B2 Immune and/or inflammatory disorders; autoimmune disorders; disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1); antagonize CD11/CD18 receptors associated with leukocytes. SUNESIS PHARMACEUTICALS, INC. (US) 2008-01-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176896-A1 Modulators of cellular adhesion ITGB1, VCAM1, ITGB8 SSTR4 3719/4885PTGS1 1577/4885PTGS2 3626/4885
US-20090124625-A1 NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS GRM5, GRM2, GRM1 SSTR4 659/4885PTGS1 1912/4885PTGS2 2124/4885
US-20240238425-A1 HSD17B13 Inhibitors and/or Degraders HSD17B13, HSD17B3, HSD17B1 SSTR4 2086/4885PTGS1 1514/4885PTGS2 1680/4885
US-20230322721-A1 TRIAZOLE DERIVATIVES AND THEIR USE AS TANKYRASE INHIBITORS CBR3, GBA3, TECR SSTR4 889/4885PTGS1 367/4885PTGS2 782/4885
US-12016852-B2 Pyrrolidine glycosidase inhibitors PREP, GAA, DNPEP SSTR4 2699/4885PTGS1 3107/4885PTGS2 3349/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI SSTR4 2449/4885PTGS1 600/4885PTGS2 897/4885
US-12043613-B2 Inhibitors of SARM1 SARM1, SMN1; SMN2, SARNP SSTR4 4385/4885PTGS1 4277/4885PTGS2 4451/4885
US-20080146539-A1 NEW CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS OAT, ASS1, OTC SSTR4 2192/4885PTGS1 958/4885PTGS2 1474/4885
US-20230295115-A1 SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME HCCS, HAVCR2, HDGF SSTR4 2888/4885PTGS1 3571/4885PTGS2 3450/4885
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 SSTR4 4749/4885PTGS1 2379/4885PTGS2 2854/4885
US-20080182839-A1 MODULATORS OF CELLULAR ADHESION ITGB1, VCAM1, ITGB8 SSTR4 3725/4885PTGS1 1572/4885PTGS2 3620/4885
US-11795165-B2 Tetrahydro-benzoazepine glycosidase inhibitors BACE1, BACE2, BCHE SSTR4 2070/4885PTGS1 2975/4885PTGS2 2884/4885
US-20090197883-A1 Diphenyl Substituted Cycloalkanes, Compositions Containing Such Compounds and Methods Of Use ALOX5, LTC4S, ALOX15B SSTR4 2970/4885PTGS1 9/4885PTGS2 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.